Status:
COMPLETED
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
30-75 years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.
Eligibility Criteria
Inclusion
- Subjects with type 2 diabetes
- Duration of diabetes at least 3 months
- Both diet treated and patients in therapy with OHA (oral hypoglycemic agents)
- Body Mass Index maximum 40 kg/m\^2
- HbA1c based on analysis from central laboratory: Between 7.5-10.0%, both inclusive, for diet treated, or maximum 9.0% for OHA treated
Exclusion
- Liver or renal disease
- Cardiac problems
- Uncontrolled treated/untreated hypertension
- Proliferative retinopathy
- Recurrent severe hypoglycaemia as judged by the Investigator
- Known or suspected allergy to trial product or related products
- Use of any drug (except for OHAs) which in the Investigator's opinion could interfere with the blood glucose level
Key Trial Info
Start Date :
October 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2001
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT01509755
Start Date
October 1 2000
End Date
October 1 2001
Last Update
January 24 2017
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Århus C, Denmark, 8000
2
Novo Nordisk Investigational Site
Copenhagen, Denmark, 2400
3
Novo Nordisk Investigational Site
Hvidovre, Denmark, 2650
4
Novo Nordisk Investigational Site
Kolding, Denmark, 6000